Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.   - palmpalidone palmitate - skizofrenija - psikolettiċi - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - fentanyl hydrochloride - uġigħ, wara l-operazzjoni - analġeżiċi - tmexxija ta ' moderat akuta għal uġigħ qawwi tuża għall-użu fi sptar issettjar biss.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - becaplermin - wound healing; skin ulcer - preparazzjonijiet għat-trattament ta 'feriti u ulċeri - regranex huwa indikat, b ' assoċjazzjoni ma ' oħra miżuri ta ' kura tajba ferita, biex jippromwovu granulazzjoni u b'hekk il-fejqan ta ' sħiħa tal-ħxuna, neuropathic, kroniċi, diabetic ulċeri inqas minn jew ugwali għal 5 cm2.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - palmpalidone palmitate - skizofrenija - psikolettiċi - trevita, injezzjoni ta '3 xhur, hija indikata għat-trattament ta' manteniment ta 'l-iskiżofrenja f'pazjenti adulti li huma klinikament stabbli fuq prodott ta' paliperidone palmitat wieħed li jista 'jiġi injettat kull xahar.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaċċini - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - epatite Ċ, kronika - antivirali għal użu sistemiku - incivo, f'kombinazzjoni ma 'peginterferon alfa u ribavirin, huwa indikat għall-kura tal-ġenotip-1 epatite Ċ kronika f'pazjenti adulti b'mard kumpensat tal-fwied (inkluż ċirrożi):li huma trattament naïve;li jkunu diġà ġew ittrattati b'interferon alfa (pegylated jew mhux pegylated) waħdu jew f'kombinazzjoni ma' ribavirin, inkluż relapsers, dawk li wrew rispons parzjali u dawk li rrispondew null.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibatteriċi għal użu sistemiku, - doribax huwa indikat għall-kura ta 'l-infezzjonijiet li ġejjin fl-adulti:pnewmonja nożokomjali (inkluż pulmonite assoċjata ma'); infezzjonijiet intra-addominali;ikkumplikati tal-passaġġ urinarju. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - simeprevir - epatite Ċ, kronika - antivirali għal użu sistemiku - olysio huwa indikat flimkien ma 'prodotti mediċinali oħra għall-kura ta' l-epatite Ċ kronika (chc) f'pazjenti adulti. għall-vajrus tal-epatite Ċ (hcv) ġenotip attività speċifika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.   - macitentan - pressjoni għolja, pulmonari - għal pressjoni għolja, - opsumit, bħala monoterapija jew flimkien, huwa indikat għat-trattament fit-tul ta 'pressjoni għolja arterjali pulmonari (pah) f'pazjenti adulti tal-klassi funzjonali tal-who (fc) ii sa iii. l-effikaċja ġiet murija fil-pah popolazzjoni inkluż idjopatika u li tintiret mill-pah, li l-pah assoċjata mal-connective tissue, u pah assoċjata ma kkoreġuti sempliċi mard tal-qalb konġenitali.